Literature DB >> 9506530

Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids.

M Wartenberg1, C Frey, H Diedershagen, J Ritgen, J Hescheler, H Sauer.   

Abstract

Growing multicellular prostate tumor spheroids develop quiescent cell subpopulations in central regions with features of intrinsic multicell-mediated drug resistance. Doxorubicin (dox) uptake was significantly reduced in large spheroids (diameter 400+/-70 microm), which consist predominantly of quiescent cells, as compared to small spheroids (diameter 100+/-50 microm), which consist entirely of proliferating cells. After removal of dox from the incubation medium, dox fluorescence declined more efficiently in large spheroids, which led to a decreased dox toxicity as revealed by colony-forming assays. Verapamil significantly increased dox retention in large spheroids and, consequently, augmented dox toxicity. At a depth 80 microm from the spheroid periphery, a significantly decreased dox fluorescence was observed in the deep, quiescent cell layers of large spheroids. The P-glycoprotein-mediated multidrug resistance (MDR)-reversing agents verapamil, cyclosporin A, quinidine, sodium orthovanadate and tamoxifen significantly increased dox fluorescence at this depth, whereas genistein, indomethacin, probenecid and brefeldin A, which reverse multidrug-resistance-associated protein (MRP) function, exerted no effect. Anti-P-glycoprotein immunohistochemistry of multicellular tumor spheroids revealed an increase of P-glycoprotein expression in large speroids as compared to small spheroids, which was most prominent in the Ki-67-negative, quiescent cell layers 60 to 100 microm distant from the periphery of the spheroid, indicating that the MDR phenotype is related to cell quiescence. This was corroborated by whole-cell patch-clamp experiments, where the C219 antibody, which is directed against the ATP-binding site of P-glycoprotein, significantly inhibited P-glycoprotein-associated, volume-activated chloride currents in quiescent, but not proliferating cells from multicellular tumor spheroids.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506530     DOI: 10.1002/(sici)1097-0215(19980316)75:6<855::aid-ijc7>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Simulation of the delivery of doxorubicin to hepatoma.

Authors:  Y M Goh; H L Kong; C H Wang
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Restructuring dynamics of DU 145 and LNCaP prostate cancer spheroids.

Authors:  Hong Song; Shamik K Jain; Richard M Enmon; Kim C O'Connor
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Sep-Oct       Impact factor: 2.416

3.  Spheroid-based drug screen: considerations and practical approach.

Authors:  Juergen Friedrich; Claudia Seidel; Reinhard Ebner; Leoni A Kunz-Schughart
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

4.  Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.

Authors:  Nathalia Daflon-Yunes; Flavio Eduardo Pinto-Silva; Raphael Silveira Vidal; Bruna Fortunato Novis; Tandressa Berguetti; Raphael Rodrigues Soares Lopes; Carla Polycarpo; Vivian M Rumjanek
Journal:  Mol Cell Biochem       Date:  2013-07-23       Impact factor: 3.396

5.  Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.

Authors:  Federico Perche; Niravkumar R Patel; Vladimir P Torchilin
Journal:  J Control Release       Date:  2012-09-10       Impact factor: 9.776

6.  Priming cancer cells for drug resistance: role of the fibroblast niche.

Authors:  Wei Bin Fang; Min Yao; Nikki Cheng
Journal:  Front Biol (Beijing)       Date:  2014-02-01

7.  Tumor cell imaging using the intrinsic emission from PAMAM dendrimer: a case study with HeLa cells.

Authors:  Bijesh K Biswal; Manniledam Kavitha; R S Verma; Edamana Prasad
Journal:  Cytotechnology       Date:  2009-11-12       Impact factor: 2.058

8.  Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Authors:  Paul D Bonnitcha; Simon R Bayly; Mark B M Theobald; Helen M Betts; Jason S Lewis; Jonathan R Dilworth
Journal:  J Inorg Biochem       Date:  2009-10-24       Impact factor: 4.155

9.  Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Stuart S Winter; Zeyu Jiang; Hadya M Khawaja; Timothy Griffin; Meenakshi Devidas; Barbara L Asselin; Richard S Larson
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

10.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Authors:  Krupa J Patel; Ian F Tannock
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.